Regulation of Vascular Homeostasis by Nitric Oxide

References
1 Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6
2 Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6
3 Moncada S. The 1991 Ulf von Euler Lecture. The L-arginine:nitric oxide pathway. Acta Physiol Scand 1992; 145: 201-27
4 Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 1991; 351: 714-8
5 Lyons CR, Orloff GJ, Cunningham JM. Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line. J Biol Chem 1992; 267: 6470-4
6 Stuehr D, Griffith OW. Mammalian nitric oxide synthases. In: Advances in Enzymology and Related Areas of Molecular Biology. Stuch DJ. et al. (eds). 1992; vol. 65 pp. 287-346
7 Palmer RMJ, Moncada S. A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun 1989; 158: 348-52
8 Forstermann U, Pollock J, Schmidt HHHW, Heller M, Murad F. Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991; 88: 1788-92
9 Marsden PA, Shappert KT, Chen HS, Flowers M, Sundell CL, Wilcox JN, Lamas S, Michel T. Molecular cloning and characterization of human endothelial nitric oxide synthase. FEBS Lett 1992; 307: 287-93
10 Sessa WV, Harrison JK, Barber CM, Zeng D, Durieux ME, D'Angelo DD, Lynch KR, Peach MJ. Molecular cloning and expression of a cDNA encoding endothelial cell nitric oxide synthase. J Biol Chem 1992; 267: 15274-6
11 Moncada S, Palmer RMJ, Higgs EA. Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol 1989; 38: 1709-15
12 Cooke JP, Rossitch E, Andon Jr NA, Loscalzo J, Dzau VJ. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J Clin Invest 1991; 88: 1663-71
13 Radomski MW, Palmer RMJ, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990; 87: 5193-7
14 Radomski MW, Palmer RMJ, Moncada S. Characterization of the L-arginine:nitric oxide pathway in human platelets. Br J Pharmacol 1990; 101: 325-8
15 Radomski MW, Palmer RMJ, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA 1990; 87: 10043-7
16 Rees DD, Cellek S, Palmer RMJ, Moncada S. Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun 1990; 173: 541-7
17 McCall T, Palmer RMJ, Moncada S. Induction of nitric oxide synthase in rat peritoneal neutrophils and its inhibition by dexamethasone and the cytokine interleukin-8. In: The Biology of Nitric Oxide. Part 2. Enzymology, Biochemistry and Immunology. Moncada S, Marietta MA, Hibbs Jr JB, Higgs EA. (eds) Portland Press; London: 1992. pp. 140-4
18 Lelchuk R, Radomski MW, Martin JF, Moncada S. Constitutive and inducible nitric oxide synthases in human megakaryoblastic cells. J Pharmacol Exp Ther 1992; 262: 1220-4
19 McCall TB, Boughton-Smith NK, Palmer RMJ, Whittle BJR, Moncada S. Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide ion. Biochem J 1989; 261: 293-6
20 Hung NCA. Goldin RD: Nitric oxide production by monocytes in alcoholic liver disease. J Hepatol 1992; 14: 146-50
21 Hibbs Jr JB, Taintor RR, Vavrin Z, Granger DL, Drapier JC, Amber IJ, Lancaster Jr JR. Synthesis of nitric oxide from a terminal guanidino atom of L-arginine: a molecular mechanism regulating cellular proliferation that targets intracellular iron. In: Nitric Oxide from L-Arginine. A Bioregulatory System. Moncada S. Higgs EA. (eds) Elsevier; Amsterdam: 1990. pp. 189-223
22 Denis M. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M. avium. Killing effector mechanism depends on the generation of reactive nitrogen intermediates. J Leukocyte Biol 1991; 48: 380-7
23 Sherman MP, Loro ML, Wong VZ, Tashkin DP. Cytokine- and Pneumocystis carini-induced L-arginine oxidation by murine and human pulmonary alveolar macrophages. J Protozool 1991; 38: 2349-69
24 Craven PA, DeRubertis FR. Restoration of the responsiveness of purified guanylate cyclase to nitrosoguanidine, nitric oxide, and related activators by heme and hemeproteins. Evidence for involvement of the paramagnetic nitrosyl-heme complex in enzyme activation. J Biol Chem 1978; 253: 8433-43
25 Ignarro LJ, Wood KS, Wolin MS. Activation of purified soluble guanylate cyclase by protoporphyrin IX. Proc Natl Acad Sci USA 1982; 79: 2870-3
26 Walter U. Physiological role of cGMP and cGMP-dependent protein kinase in the cardiovascular system.. Rev Physiol Biochem Pharmacol 1989; 113: 41-88
27 Matsuoka I, Nakahata N, Nakanishi H. Inhibitory effect of 8-bromo cyclic GMP on an extracellular Ca²⁺-dependent arachidonic acid liberation in collagen-stimulated rabbit platelets. Biochem Pharmacol 1989; 38: 1841-7
28 Nakashima S, Tohmatsu T, Hattori H, Okano Y, Nozawa Y. Inhibitory action of cyclic GMP on secretion, polyphosphoinositide hydrolysis and calcium mobilization in thrombin-stimulated human platelets. Biochem Biophys Res Commun 1986; 135: 1099-1104
29 Geiger J, Nolte C, Butt E, Sage SO, Walter U. Role of cGMP and cGMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets. Proc Natl Acad Sci USA 1992; 89: 1031-5
30 Morgan RO, Newby AC. Nitroprusside differentially inhibits ADP-stimulated calcium influx and mobilization in human platelets. Biochem J 1989; 258: 447-54
31 Johansson JS, Hayness DH. Cyclic GMP increases the rate of the calcium extrusion pump in intact human platelets but has no direct effect on the dense tubular calcium accumulation system. Biochim Biophys Acta 1992; 1105: 40-50
32 Radomski MW, Palmer RMJ, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987; 92: 181-7
33 Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 2: 1057-8
34 Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987; 148: 1482-9
35 Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92: 639-46
36 Radomski MW, Palmer RMJ, Moncada S. Isolation and washing of human platelets with nitric oxide. Thromb Res 1988; 50: 537-46
37 Palmer RMJ, Bridge L, Foxwell NA, Moncada S. The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids.. Br J Pharmacol 1992; 105: 11-2
38 Lapetina E. The toxic effects of nitric oxide might be due to the nitric oxide-induced S-nitrosylation and ADP-ribosylation of glycer-aldehyde-3-phosphate dehydrogenase. J Vase Med Biol 1991; 3: 442
39 Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, Singel D, Valeri CR, Loscalzo J. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 1992; 89: 7674-7
40 Mellion BT, Ignarro LJ, Myers CB, Ohlstein EH, Ballot BA, Hyman AL, Kadowitz PJ. Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation. Mol Pharmacol 1983; 23: 653-64
41 Radomski MW, Rees DD, Dutra A, Moncada S. S-nitroso-glu-tathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol 1992; 107: 745-9
42 Westenberger U, Thanner S, Ruf HF, Gersonde K, Sutter G, Trentz O. Formation of free radicals and nitric oxide derivative of hemoglobin in rats during shock syndrome. Free Rad Res Commun 1990; 11: 167-78
43 Rees DD, Moncada S. Induction by endotoxin of a Ca²⁺-independent nitric oxide synthase in the vasculature and its pathological role in endotoxin shock. In: Clinical Relevance of Nitric Oxide in the Cardiovascular System. Moncada S, Higgs EA, Berrazueta JR. (eds). EDICOMPLET SA; Madrid: 1991. pp. 69-87
44 Marcus AJ, Zucker MB. The Physiology of Blood Platelets. Grune & Stratton Inc; New York, London: 1965
45 Goldberg ND, Haddox MK, Nicol SE, Glass DB, Sanford CH, Kuehl Jr FA, Estensen R. Biological regulation through opposing influences of cyclic GMP and cyclic AMP: The yin yang hypothesis. In (Advances in Cyclic Nucleotide Research; vol 5). Drummond GI, Greengard P, Robison GA. (eds) Raven Press; New York: 1975. pp. 307-30
46 Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3',5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981; 57: 946-55
47 Pronai L, Ichimori K, Nozaki H, Nakazawa H, Okino H, Carmichael AJ, Arroyo CM. Investigation of the existence and biological role of L-arginine/nitric oxide pathway in human platelets by spin-trap-ping/EPR studies. Eur J Biochem 1991; 202: 923-30
48 Sane DC, Bielawska A, Greenberg CS, Hannun YA. Cyclic GMP analogs inhibit γ-thrombin-induced arachidonic acid release in human platelets. Biochem Biophys Res Commun 1989; 165: 708-14
49 Sneddon JM, Vane JR. Endothelium-derived relaxing factor reduces platelet adhesion to bovine endothelial cells. Proc Natl Acad Sci USA 1988; 85: 2800-4
50 Graaf de JC, Banga JD, Moncada S, Palmer RMJ, de Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 1992; 85: 2284-90
51 Pohl U, Busse R. EDRF increases cyclic GMP in platelets during passage through the coronary vascular bed. Circ Res 1989; 65: 1798-1803
52 Venturini CM, Del Vecchio PJ, Kaplan JE. Thrombin induced platelet adhesion to endothelium is modified by endothelial derived relaxing factor (EDRF). Biochem Biophys Res Commun 1989; 159: 349-54
53 Radomski MW, Moncada S. Role of nitric oxide in endothelial cell-platelet interactions. In: Antithrombotics. Pathophysiological Rationale for Pharmacological Interventions. Herman AG. (ed) Kluwer Academic Publishers; Dordrecht: 1991. pp. 27-48
54 Bhardwaj R, Page CP, May GR, Moore PK. Endothelium-derived relaxing factor inhibits platelet aggregation in human whole blood in vitro and in the rat in vivo. Eur J Pharmacol 1988; 157: 83-91
55 Hogan JC, Lewis MJ, Henderson AH. In vivo EDRF activity influences platelet function. Br J Pharmacol 1988; 94: 1020-2
56 Humphries RG, Tomlinson W, O'Connor SE, Leff P. Inhibition of collagen- and ADP-induced platelet aggregation by substance P in vivo: Involvement of endothelium-derived relaxing factor. J Cardio-vasc Pharmacol 1990; 16: 292-7
57 Stamler JS, Vaughan DE, Loscalzo J. Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1, and glyceryl trinitrate. Circ Res 1989; 65: 796-804
58 Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: Inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 1990; 37: 671-81
59 Moncada S, Gryglewski RJ, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-5
60 Venturini CM, Weston LK, Kaplan JE. Platelet cGMP but not cAMP, inhibits thrombin-induced platelet adhesion to pulmonary vascular endothelium. Am J Physiol 1992; 32: H606-H612
61 Chester AH, O'Neil GS, Moncada S, Tadjkarimi S, Yacoub MH. Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet 1990; 336: 897-900
62 Verbeuren TJ, Jordaens FH, Zonnekeyn LL, Van Hove CE, Coene MC, Herman AG. Effect of hypercholesterolemia on vascular reactivity in the rabbit. I. Endothelium-dependent and endothelium-independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits. Circ Res 1986; 58: 552-64
63 Barrett ML, Willis AL, Vane JR. Inhibition of platelet-derived mitogen release by nitric oxide (EDRF). Agents and Actions 1989; 27: 488-91
64 Scott-Burden T, Vanhoutte PM. Regulation of vascular smooth muscle cell proliferation: Role of endothelium-derived relaxing factor (nitric oxide). J Vasc Biol 1991; 3: 445-6
65 Ross R, Glomset JA. The pathogenesis of atherosclerosis (First of two parts). New Engl J Med 1976; 295: 369-77
66 Ross R, Glomset JA. The pathogenesis of atherosclerosis (Second of two parts). New Engl J Med 1976; 295: 420-25
67 Cooke JP, Tsao P. Cellular mechanisms of atherogenesis and the effects of nitric oxide. Curr Opin Cardiol 1992; 7: 799-804
68 Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338: 1546-50
69 Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992; 90: 1248-53
70 Egashira K, Inou T, Hirooka Y, Yamada A, Maruoka Y, Kai H, Sugimachi M, Suzuki S, Takeshita A. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 1993; 91: 29-37
71 Calver A, Collier J, Moncada S, Vallance P. Effect of local infusion of NG-monomethyl-L-arginine in patients with hypertension. The nitric oxide dilator mechanism appears abnormal. J Hypertens 1992; 10: 1025-31
72 Cadwgan T, Benjamin N. Reduced platelet nitric oxide synthesis in essential hypertension. J Vasc Biol 1991; 3: 455A
73 Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992; 90: 2548-54
74 Hamet P, Skuherska R, Pang SC, Tremblay J. Abnormalities of platelet function in hypertension and diabetes. Hypertension 1985; 7 (Suppl. 02) II-135-II-142
75 Rosenblum WI, Nelson GH, Povlishock JT. Laser-induced endothelial damage inhibits endothelium-dependent relaxation in the cerebral microcirculation of the mouse. Circ Res 1987; 60: 169-76
76 May GR, Crook P, Moore PK, Page CP. The role of nitric oxide as an endogenous regulator of platelet and neutrophil activation within the pulmonary circulation of the rabbit. Br J Pharmacol 1991; 102: 759-63
77 Herbaczynska-Cedro K, Lembowicz K, Pytel B. NG-monomethyl-L-arginine increases platelet deposition on damaged endothelium in vivo. A scanning electron microscopy study. Thromb Res 1991; 64: 1-9
78 Radomski M, Herbaczynska-Cedro K, Ceremuzynski L. Increased activity of circulating polymorphonuclear leukocytes in acute myocardial infarction. Int J Cardiol 1990; 27: 392-3
79 Luscher TF, Yang Z, Diederich D, Buhler FR. Endothelium-derived vasoactive substances: Potential role in hypertension, atherosclerosis, and vascular occlusion. J Cardiovasc Pharmacol 1989; 14: S63-S69
80 Ialenti A, Ianaro A, Moncada S, Di Rosa M. Modulation of acute inflammation by endogenous nitric oxide. Eur J Pharmacol 1992; 211: 177-82
81 Mulligan MS, Hevel JM, Marietta MA, Ward PA. Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci USA 1991; 88: 6338-42
82 Radomski MW, Vallance P, Whitley G, Foxwell N, Moncada S. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine-induced nitric oxide. Cardiovasc Res, in press;
83 Durante W, Schini VB, Scott-Burden T, Junquero DC, Kroll MH, Vanhoutte PM, Schafer AI. Platelet inhibition by an L-arginine-derived substance released by IL-lβ-treated vascular smooth muscle cells. Am J Physiol 1991; 261: H2024-H2030
84 Corrigan Jr JJ, Ray W, May N. Changes in the blood coagulation system associated with septicemia. New Engl J Med 1968; 279: 851-6
85 Petros A, Bennett D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991; 338: 1557-8
86 Remuzzi G, Perico N, Zoja C, Corna D, Macconi D, Vigano G. Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. J Clin Invest 1990; 86: 1768-71
87 Gordge MP, Neild GH. Platelets from patients on haemodialysis show impaired responses to nitric oxide. Clin Sci 1992; 83: 313-8
88 Feelisch M, Noack EA. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 1987; 139: 19-30
89 Gebalska J. Platelet adhesion and aggregation in relation to clinical course of acute myocardial infarction. M.D. thesis Warsaw (in Polish):
90 Plotkine M, Allix M, Guillou J, Boulu R. Oral administration of isosorbide dinitrate inhibits arterial thrombosis in rats. Eur J Pharmacol 1991; 201: 115-6
91 Sinzinger H, Virgolini I, O'Grady J, Rauscha F, Fitscha P. Modification of platelet function by isosorbide dinitrate in patients with coronary artery disease. Thromb Res 1992; 65: 323-35
92 Wautier JL, Weill D, Kadeva H, Maclouf J, Soria C. Modulation of platelet function by SIN-1A. J Cardiovasc Pharmacol 1989; 14: S111-S114
93 Sinzinger H, Fitscha P, O'Grady J, Rauscha F, Rogatti W, Vane JR. Synergistic effect of prostaglandin E1 and isosorbide dinitrate in peripheral vascular disease. Lancet 1990; 335: 627-8
94 Sinzinger H, Rauscha F, O'Grady J, Fitscha P. Prostaglandin I2 and the nitric oxide donor molsidomine have synergistic effects on thromboresistance in man. Br J Clin Pharmacol 1992; 33: 289-92
95 Groves PH, Penny WJ, Cheadle HA, Lewis MJ. Exogenous nitric oxide inhibits in vivo platelet adhesion following balloon angioplasty. Cardiovasc Res 1992; 26: 615-9
96 Aono J, Sugawa M, Koide T, Takato M. The role of cGMP in the anti-aggregating properties of BY1949, a novel dibenzoxazepine derivative. Eur J Pharmacol 1991; 195: 225-31
97 Sakuma I, Akoishi Y, Fukao M, Makita Y, Makita MA, Miyazaki T, Yasuda H. Dipyridamole potentiates the antiaggregating effect of EDRF. Thromb Res Suppl 1990; 12: 87-9
98 Bult H, Fret AR, Jordaens FH, Herman G. Dipyridamole potentiates the antiaggregating and vasodilator activity of nitric oxide. Eur J Pharmacol 1991; 199: 1-8
99 Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320: 454-6
100 Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620-4